Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma.

Abstract

PURPOSE:

To evaluate the effect of tafluprost on the central corneal thickness (CCT) in patients with primary open-angle glaucoma (POAG).

METHODS:

This was a prospective study and included 100 eyes of 54 patients with POAG. All patients received tafluprost 0.0015% (Saflutan®) once daily in one or both eyes. CCT was measured by using noncontact pachymetry prior to the treatment and after 6 and 12 months.

RESULTS:

Mean CCT of all treated eyes (n = 100) was 547.79 ± 29.48 μm at baseline, 535.61 ± 26.54 μm after 6 months and 533.55 ± 26.45 μm after 12 months (Student's t test, p < 0.0001). Ninety-three percent of all treated eyes showed a decrease of CCT. CCT reduction was more significant within the first six months of the treatment period (Student's t test, p < 0.0001). After 12 months, a CCT reduction >25 μm occurred in 5% of all treated eyes. There was a significant positive correlation between the magnitude of corneal thinning and the initial CCT (Pearson, r = 0.49, p < 0.0001) but not between the magnitude of corneal thinning and intraocular pressure (IOP) reduction (Pearson, r = 0.145, p = 0.15).

DISCUSSION:

Long-term use of tafluprost may decrease the CCT in patients with POAG. Consequently, clinicians must be aware of prolongated CCT variations that may arise throughout the follow-up period for proper IOP targeting and management.

• Authors: Georgios D Panos, Aristeidis Konstantinidis, Efstratios Mendrinos, Vassilios Kozobolis, Irfan Perente, Zisis Gatzioufas
• Journal: Current eye research (Curr Eye Res) Vol. 38 Issue 9 Pg. 977-82 (Sep 2013) ISSN: 1460-2202 [Electronic] England
• PMID: 23713521 (Publication Type: Controlled Clinical Trial, Journal Article)

Chemical References

• Prostaglandins F
• tafluprost
• Dinoprost

Topics

• Adult
• Aged
• Aged, 80 and over
• Cornea (drug effects, pathology)
• Dinoprost (analogs & derivatives)
• Female
• Follow-Up Studies
• Glaucoma, Open-Angle (drug therapy, pathology)
• Humans
• Intraocular Pressure (drug effects)
• Male
• Middle Aged
• Prospective Studies
• Prostaglandins F (administration & dosage)
• Treatment Outcome